Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies

Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2

Yang, 2019, A global view of hepatocellular carcinoma: Trends, risk, prevention and management, Nat. Rev. Gastroenterol. Hepatol., 16, 589, 10.1038/s41575-019-0186-y

Galle, 2018, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma, J. Hepatol., 69, 182, 10.1016/j.jhep.2018.03.019

Llovet, 2018, Molecular therapies and precision medicine for hepatocellular carcinoma, Nat. Rev. Clin. Oncol., 15, 599, 10.1038/s41571-018-0073-4

Llovet, 2016, Hepatocellular carcinoma, Nat. Rev. Dis. Primers, 2, 16018, 10.1038/nrdp.2016.18

Potter, 2016, The Warburg effect: 80 years on, Biochem. Soc. Trans., 44, 1499, 10.1042/BST20160094

Pavlova, 2016, The Emerging Hallmarks of Cancer Metabolism, Cell Metab., 23, 27, 10.1016/j.cmet.2015.12.006

Fu, Y., and Chung, F.-L. (2018). Oxidative stress and hepatocarcinogenesis. Hepatoma Res., 4.

Marra, 2011, Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: An overview, J. Transl. Med., 9, 171, 10.1186/1479-5876-9-171

Wang, 2016, Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets, Oxidative Med. Cell. Longev., 2016, 7891574, 10.1155/2016/7891574

Sosa, 2013, Oxidative stress and cancer: An overview, Ageing Res. Rev., 12, 376, 10.1016/j.arr.2012.10.004

Ragusa, 2018, Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities, Oxidative Med. Cell. Longev., 2018, 1

Amann, 2009, GLUT1 Expression Is Increased in Hepatocellular Carcinoma and Promotes Tumorigenesis, Am. J. Pathol., 174, 1544, 10.2353/ajpath.2009.080596

Xia, H., Chen, J., Gao, H., Kong, S.N., Deivasigamani, A., Shi, M., Xie, T., and Hui, K.M. (2019). Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma. Eur. J. Nucl. Med. Mol. Imaging.

Lei, Y., Hu, Q., and Gu, J. (2019). Expressions of Carbohydrate Response Element Binding Protein and Glucose Transporters in Liver Cancer and Clinical Significance. Pathol. Oncol. Res.

Guzman, 2015, Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma, Dig. Dis. Sci., 60, 420, 10.1007/s10620-014-3364-3

Chai, 2019, Caveolin enhances hepatocellular carcinoma cell metabolism, migration, and invasion in vitro via a hexokinase 2-dependent mechanism, J. Cell. Physiol., 234, 1937, 10.1002/jcp.27074

Mathupala, 1997, Aberrant glycolytic metabolism of cancer cells: A remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase, J. Bioenerg. Biomembr., 29, 339, 10.1023/A:1022494613613

Wyatt, E., Wu, R., Rabeh, W., Park, H.-W., Ghanefar, M., and Ardehali, H. (2010). Regulation and cytoprotective role of hexokinase III. PLoS ONE, 5.

Ludvik, 2016, HKDC1 Is a Novel Hexokinase Involved in Whole-Body Glucose Use, Endocrinology, 157, 3452, 10.1210/en.2016-1288

Mathupala, 2006, Hexokinase II: Cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria, Oncogene, 25, 4777, 10.1038/sj.onc.1209603

Ausina, 2018, Insulin specifically regulates expression of liver and muscle phosphofructokinase isoforms, Biomed. Pharmacother., 103, 228, 10.1016/j.biopha.2018.04.033

Lee, N.C.W., Carella, M.A., Papa, S., and Bubici, C. (2018). High Expression of Glycolytic Genes in Cirrhosis Correlates with the Risk of Developing Liver Cancer. Front. Cell Dev. Biol., 6.

Feng, 2020, A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma, Cell Death Dis., 11, 89, 10.1038/s41419-020-2278-6

Liu, 2017, Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase, Hepatology, 66, 631, 10.1002/hep.29202

Kunjithapatham, 2012, Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma, Oncotarget, 3, 940, 10.18632/oncotarget.623

Wong, C.C.-L., Au, S.L.-K., Tse, A.P.-W., Xu, I.M.-J., Lai, R.K.-H., Chiu, D.K.-C., Wei, L.L., Fan, D.N.-Y., Tsang, F.H.-C., and Lo, R.C.-L. (2014). Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis. PLoS ONE, 9.

Christofk, 2008, The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth, Nature, 452, 230, 10.1038/nature06734

Miao, 2013, Lactate dehydrogenase A in cancer: A promising target for diagnosis and therapy, IUBMB Life, 65, 904, 10.1002/iub.1216

Yada, 2016, The prognostic role of lactate dehydrogenase serum levels in patients with hepatocellular carcinoma who are treated with sorafenib: The influence of liver fibrosis, J. Gastrointest. Oncol., 7, 615, 10.21037/jgo.2016.03.10

Guo, 2019, Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine, Int. J. Biol. Sci., 15, 1771, 10.7150/ijbs.35094

Sheng, 2012, Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma, FEBS J., 279, 3898, 10.1111/j.1742-4658.2012.08748.x

Zhang, 2018, MicroRNA-34a inhibits liver cancer cell growth by reprogramming glucose metabolism, Mol. Med. Rep., 17, 4483

Hua, 2018, miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA, Biochem. Biophys. Res. Commun., 496, 947, 10.1016/j.bbrc.2018.01.112

Faloppi, 2016, Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New, BioMed Res. Int., 2016, 7196280, 10.1155/2016/7196280

Ohno, 2014, Aberrant expression of monocarboxylate transporter 4 in tumour cells predicts an unfavourable outcome in patients with hepatocellular carcinoma, Liver Int., 34, 942, 10.1111/liv.12466

Yorita, K., Ohno, A., Nishida, T., Kondo, K., Ohtomo, T., and Kataoka, H. (2019). Intratumoral reciprocal expression of monocarboxylate transporter 4 and glypican-3 in hepatocellular carcinomas. BMC Res. Notes, 12.

Li, 2009, HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection, Histopathology, 54, 677, 10.1111/j.1365-2559.2009.03280.x

Ke, 2014, Upregulation of CD147 protects hepatocellular carcinoma cell from apoptosis through glycolytic switch via HIF-1 and MCT-4 under hypoxia, Hepatol. Int., 8, 405, 10.1007/s12072-014-9536-6

Yang, H.-C., Wu, Y.-H., Yen, W.-C., Liu, H.-Y., Hwang, T.-L., Stern, A., and Chiu, D.T.-Y. (2019). The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer. Cells, 8.

Hong, 2014, PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis, Gut, 63, 1635, 10.1136/gutjnl-2013-305302

Barajas, 2018, The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer, Sci. Rep., 8, 9105, 10.1038/s41598-018-27358-5

Mukhopadhyay, 2015, Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization, Cell Rep., 13, 2014, 10.1016/j.celrep.2015.10.045

Hirata, 2016, Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma, Cancer Res., 76, 3265, 10.1158/0008-5472.CAN-15-2601

Liu, G.-M., and Zhang, Y.-M. (2018). Targeting FBPase is an emerging novel approach for cancer therapy. Cancer Cell Int., 18.

Bian, 2017, Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation, Nat. Commun., 8, 14420, 10.1038/ncomms14420

Tang, 2018, Overexpression of PCK1 Gene Antagonizes Hepatocellular Carcinoma through the Activation of Gluconeogenesis and Suppression of Glycolysis Pathways, Cell. Physiol. Biochem., 47, 344, 10.1159/000489811

Mihaylova, 2011, The AMPK signalling pathway coordinates cell growth, autophagy and metabolism, Nat. Cell Biol., 13, 1016, 10.1038/ncb2329

Shang, 2016, Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects, World J. Gastroenterol., 22, 9933, 10.3748/wjg.v22.i45.9933

Ferretti, 2019, Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: Targeting AMPK activation to control migration, Sci. Rep., 9, 2815, 10.1038/s41598-019-39556-w

Cheng, J., Huang, T., Li, Y., Guo, Y., Zhu, Y., Wang, Q., Tan, X., Chen, W., Zhang, Y., and Cheng, W. (2014). AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma. PLoS ONE, 9.

Lee, 2012, AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells, Cancer Res., 72, 4394, 10.1158/0008-5472.CAN-12-0429

Ferretti, 2016, AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation, Oncotarget, 7, 17815, 10.18632/oncotarget.7404

Xie, 2008, Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells, Circulation, 117, 952, 10.1161/CIRCULATIONAHA.107.744490

Xie, 2009, Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis, Mol. Cell. Biol., 29, 3582, 10.1128/MCB.01417-08

Chen, 2017, Hypoxia inducible factors in hepatocellular carcinoma, Oncotarget, 8, 46691, 10.18632/oncotarget.17358

Luo, 2014, The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma, BioMed Res. Int., 2014, 409272, 10.1155/2014/409272

Guo, 2020, Hypoxia-inducible factors in hepatocellular carcinoma, Oncol. Rep., 43, 3

Dai, C.-X., Gao, Q., Qiu, S.-J., Ju, M.-J., Cai, M.-Y., Xu, Y.-F., Zhou, J., Zhang, B.-H., and Fan, J. (2009). Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer, 9.

Yang, 2014, The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients’ clinical outcome, Jpn. J. Clin. Oncol., 44, 159, 10.1093/jjco/hyt194

Wang, 2009, Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis, J. Int. Med. Res., 37, 417, 10.1177/147323000903700217

Wu, L., Fu, Z., Zhou, S., Gong, J., Liu, C.A., Qiao, Z., and Li, S. (2014). HIF-1α and HIF-2α: Siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation. PLoS ONE, 9.

Feng, 2019, Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition, Int. J. Biol. Macromol., 137, 32, 10.1016/j.ijbiomac.2019.06.189

Semenza, 2012, Hypoxia-inducible factors in physiology and medicine, Cell, 148, 399, 10.1016/j.cell.2012.01.021

Gwak, 2005, Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression, J. Hepatol., 42, 358, 10.1016/j.jhep.2004.11.020

Yasuda, 2004, Hexokinase II and VEGF expression in liver tumors: Correlation with hypoxia-inducible factor 1 alpha and its significance, J. Hepatol., 40, 117, 10.1016/S0168-8278(03)00503-8

Zhou, Y., Huang, Y., Hu, K., Zhang, Z., Yang, J., and Wang, Z. (2020). HIF1A activates the transcription of lncRNA RAET1K to modulate hypoxia-induced glycolysis in hepatocellular carcinoma cells via miR-100-5p. Cell Death Dis., 11.

Zhao, 2018, Prognostic significance of NANOG expression in solid tumors: A meta-analysis, Onco Targets Ther., 11, 5515, 10.2147/OTT.S169593

Gong, 2015, Regulation of NANOG in cancer cells, Mol. Carcinog., 54, 679, 10.1002/mc.22340

Chen, 2016, NANOG metabolically reprograms tumor-initiating stem-like cells through tumorigenic changes in oxidative phosphorylation and fatty acid metabolism, Cell Metab., 23, 206, 10.1016/j.cmet.2015.12.004

Zhou, 2018, Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment, Med. Res. Rev., 38, 741, 10.1002/med.21455

Hippo, 2004, Identification of Soluble NH2 -Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma, Cancer Res., 64, 2418, 10.1158/0008-5472.CAN-03-2191

Haruyama, 2016, Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma, World J. Gastroenterol., 22, 275, 10.3748/wjg.v22.i1.275

Filmus, 2001, Glypicans: Proteoglycans with a surprise, J. Clin. Investig., 108, 497, 10.1172/JCI200113712

Capurro, 2003, Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma, Gastroenterology, 125, 89, 10.1016/S0016-5085(03)00689-9

Chen, 2014, Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy, J. Gastroenterol., 49, 117, 10.1007/s00535-013-0793-2

Shirakawa, 2009, Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma, Cancer Sci., 100, 1403, 10.1111/j.1349-7006.2009.01206.x

Yao, G., Yin, J., Wang, Q., Dong, R., and Lu, J. (2019). Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells. BioMed Res. Int., 2019.

Li, 2018, Low glucose metabolism in hepatocellular carcinoma with GPC3 expression, WJG, 24, 494, 10.3748/wjg.v24.i4.494

Cho, 2010, Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells, J. Cell. Biochem., 111, 1252, 10.1002/jcb.22848

Son, Y., Cheong, Y.-K., Kim, N.-H., Chung, H.-T., Kang, D.G., and Pae, H.-O. (2011). Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?. J. Signal Transduct., 2011.

Koundouros, 2018, Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer, Front. Oncol., 8, 160, 10.3389/fonc.2018.00160

Min, 2011, Mitogen-activated protein kinases in hepatocellular carcinoma development, Semin. Cancer Biol., 21, 10, 10.1016/j.semcancer.2010.10.011

Gailhouste, 2010, RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo, Int. J. Cancer, 126, 1367, 10.1002/ijc.24950

Bessard, 2008, RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo, Oncogene, 27, 5315, 10.1038/onc.2008.163

Ito, 1998, Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma, Hepatology, 27, 951, 10.1002/hep.510270409

Hoffmann, 2011, Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma, Anticancer Res., 31, 3883

Hui, 2008, Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation, J. Clin. Investig., 118, 3943, 10.1172/JCI37156

Hagiwara, 2012, Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma, Br. J. Cancer, 106, 1997, 10.1038/bjc.2012.145

Zamani, 2018, Gankyrin: A novel promising therapeutic target for hepatocellular carcinoma, Artif. Cells Nanomed. Biotechnol., 46, 1301, 10.1080/21691401.2017.1388250

Liu, 2019, Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma, Cancer Lett., 443, 34, 10.1016/j.canlet.2018.11.030

Hui, 2007, p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway, Nat. Genet., 39, 741, 10.1038/ng2033

Iyoda, 2003, Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma, Cancer, 97, 3017, 10.1002/cncr.11425

Polivka, 2014, Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway, Pharmacol. Ther., 142, 164, 10.1016/j.pharmthera.2013.12.004

Yang, 2019, Targeting PI3K in cancer: Mechanisms and advances in clinical trials, Mol. Cancer, 18, 26, 10.1186/s12943-019-0954-x

Chen, 2009, Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9, Hepatol. Res., 39, 177, 10.1111/j.1872-034X.2008.00449.x

Grabinski, 2012, Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells, Mol. Cancer, 11, 85, 10.1186/1476-4598-11-85

Cleary, 2013, Identification of driver genes in hepatocellular carcinoma by exome sequencing, Hepatology, 58, 1693, 10.1002/hep.26540

Janku, 2014, Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing, Oncotarget, 5, 3012, 10.18632/oncotarget.1687

Cao, H., Xu, Z., Wang, J., Cigliano, A., Pilo, M.G., Ribback, S., Zhang, S., Qiao, Y., Che, L., and Pascale, R.M. (2019). Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer, 19.

Matter, 2014, Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends, J. Hepatol., 60, 855, 10.1016/j.jhep.2013.11.031

Guichard, 2012, Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat. Genet., 44, 694, 10.1038/ng.2256

Vassalli, 2019, Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells, Stem Cells Int., 2019, 3904645, 10.1155/2019/3904645

Ma, 2013, Role of Nrf2 in Oxidative Stress and Toxicity, Annu. Rev. Pharmacol. Toxicol., 53, 401, 10.1146/annurev-pharmtox-011112-140320

Schieber, 2014, ROS Function in Redox Signaling and Oxidative Stress, Curr. Biol., 24, R453, 10.1016/j.cub.2014.03.034

Zhang, M., Zhang, C., Zhang, L., Yang, Q., Zhou, S., Wen, Q., and Wang, J. (2015). Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer, 15.

Liu, 2020, TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway, Nat. Commun., 11, 348, 10.1038/s41467-019-14190-2

DeNicola, 2011, Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis, Nature, 475, 106, 10.1038/nature10189

Zavattari, 2015, Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis, Hepatology, 62, 851, 10.1002/hep.27790

The Cancer Genome Atlas Research Network (2017). Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 169, 1327–1341.e23.

Ngo, 2017, Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis, Cancer Res., 77, 4797, 10.1158/0008-5472.CAN-16-3538

Ciccarone, 2019, Oxidative Stress-Driven Autophagy acROSs Onset and Therapeutic Outcome in Hepatocellular Carcinoma, Oxidative Med. Cell. Longev., 2019, 6050123, 10.1155/2019/6050123

Sies, 1999, Glutathione and its role in cellular functions, Free Radic. Biol. Med., 27, 916, 10.1016/S0891-5849(99)00177-X

Huang, 2001, Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration, FASEB J., 15, 19, 10.1096/fj.00-0445fje

Traverso, 2013, Role of glutathione in cancer progression and chemoresistance, Oxidative Med. Cell. Longev., 2013, 972913, 10.1155/2013/972913

Fu, 2018, Autophagy activation contributes to glutathione transferase Mu 1-mediated chemoresistance in hepatocellular carcinoma, Oncol. Lett., 16, 346

Cheng, S.-B., Liu, H.-T., Chen, S.-Y., Lin, P.-T., Lai, C.-Y., and Huang, Y.-C. (2017). Changes of Oxidative Stress, Glutathione, and Its Dependent Antioxidant Enzyme Activities in Patients with Hepatocellular Carcinoma before and after Tumor Resection. PLoS ONE, 12.

Pljesa-Ercegovac, M., Savic-Radojevic, A., Matic, M., Coric, V., Djukic, T., Radic, T., and Simic, T. (2018). Glutathione Transferases: Potential Targets to Overcome Chemoresistance in Solid Tumors. Int. J. Mol. Sci., 19.

Singh, 2013, Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress, Free Radic. Biol. Med., 56, 89, 10.1016/j.freeradbiomed.2012.11.010

Sahovic, 1988, Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro, Cancer Res., 48, 1223

Husain, 2013, Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells, J. Immunol., 191, 1486, 10.4049/jimmunol.1202702

Gottfried, 2008, Tumor-induced modulation of dendritic cell function, Cytokine Growth Factor Rev., 19, 65, 10.1016/j.cytogfr.2007.10.008

Fischer, 2007, Inhibitory effect of tumor cell-derived lactic acid on human T cells, Blood, 109, 3812, 10.1182/blood-2006-07-035972

Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490

Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034

Biswas, 2012, Orchestration of metabolism by macrophages, Cell Metab., 15, 432, 10.1016/j.cmet.2011.11.013

Jayasingam, S.D., Citartan, M., Thang, T.H., Mat Zin, A.A., Ang, K.C., and Ch’ng, E.S. (2020). Evaluating the Polarization of Tumor-Associated Macrophages into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice. Front. Oncol., 9.

Wan, 2014, Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells, Gastroenterology, 147, 1393, 10.1053/j.gastro.2014.08.039

Gabrilovich, 2009, Myeloid-derived suppressor cells as regulators of the immune system, Nat. Rev. Immunol., 9, 162, 10.1038/nri2506

Bol, 2019, The clinical application of cancer immunotherapy based on naturally circulating dendritic cells, J. Immunother. Cancer, 7, 109, 10.1186/s40425-019-0580-6

Wculek, 2020, Dendritic cells in cancer immunology and immunotherapy, Nat. Rev. Immunol., 20, 7, 10.1038/s41577-019-0210-z

Maher, 2004, Targeting cytotoxic T lymphocytes for cancer immunotherapy, Br. J. Cancer, 91, 817, 10.1038/sj.bjc.6602022

Sek, K., Mølck, C., Stewart, G.D., Kats, L., Darcy, P.K., and Beavis, P.A. (2018). Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. Int. J. Mol. Sci., 19.

Idzko, 2014, Nucleotide signalling during inflammation, Nature, 509, 310, 10.1038/nature13085

Galluzzi, 2017, Immunogenic cell death in cancer and infectious disease, Nat. Rev. Immunol., 17, 97, 10.1038/nri.2016.107

Ramkumar, 2001, Adenosine, oxidative stress and cytoprotection, Jpn. J. Pharmacol., 86, 265, 10.1254/jjp.86.265

Sarti, 2018, Extracellular ATP and P2 purinergic signalling in the tumour microenvironment, Nat. Rev. Cancer, 18, 601, 10.1038/s41568-018-0037-0

Allard, 2019, Targeting the CD73-adenosine axis in immuno-oncology, Immunol. Lett., 205, 31, 10.1016/j.imlet.2018.05.001

Safford, 2005, Egr-2 and Egr-3 are negative regulators of T cell activation, Nat. Immunol., 6, 472, 10.1038/ni1193

Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., and Coukos, G. (2019). Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Front. Immunol., 10.

Wehbi, 2016, Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells—Role of Anchored Protein Kinase a Signaling Units, Front. Immunol., 7, 222, 10.3389/fimmu.2016.00222

Vang, 2013, Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: A potential role for Epac, Biochem. J., 456, 463, 10.1042/BJ20130064

Novitskiy, 2008, Adenosine receptors in regulation of dendritic cell differentiation and function, Blood, 112, 1822, 10.1182/blood-2008-02-136325

Panther, 2003, Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells, Blood, 101, 3985, 10.1182/blood-2002-07-2113

Li, 2012, Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury, J. Clin. Investig., 122, 3931, 10.1172/JCI63170

Kuhel, 2000, Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms, FASEB J., 14, 2065, 10.1096/fj.99-0508com

Ryzhov, 2011, Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells, J. Immunol., 187, 6120, 10.4049/jimmunol.1101225

Vasuri, 2018, Role of microRNAs in the main molecular pathways of hepatocellular carcinoma, World J. Gastroenterol., 24, 2647, 10.3748/wjg.v24.i25.2647

Liu, A.M., Xu, Z., Shek, F.H., Wong, K.-F., Lee, N.P., Poon, R.T., Chen, J., and Luk, J.M. (2014). miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma. PLoS ONE, 9.

Burchard, 2010, microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma, Mol. Syst. Biol., 6, 402, 10.1038/msb.2010.58

Thurnherr, 2016, Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways, Sci. Rep., 6, 20065, 10.1038/srep20065

Park, 2013, Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520, Hepatology, 58, 182, 10.1002/hep.26310

Fang, 2012, MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma, Hepatology, 55, 1852, 10.1002/hep.25576

Tang, 2015, miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway, Oncol. Lett., 10, 681, 10.3892/ol.2015.3264

Zhao, 2019, Targeted inhibition of MCT4 disrupts intracellular pH homeostasis and confers self-regulated apoptosis on hepatocellular carcinoma, Exp. Cell Res., 384, 111591, 10.1016/j.yexcr.2019.111591

Tirnitz-Parker, J.E.E. (2019). Multidrug Resistance in Hepatocellular Carcinoma. Hepatocellular Carcinoma, Codon Publications.

Dong, J., Zhai, B., Sun, W., Hu, F., Cheng, H., and Xu, J. (2017). Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells. PLoS ONE, 12.

Liang, 2013, Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma, Hepatology, 57, 1847, 10.1002/hep.26224

Kong, 2000, Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication, World J. Gastroenterol., 6, 134, 10.3748/wjg.v6.i1.134

Mao, 2015, Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport—An update, AAPS J, 17, 65, 10.1208/s12248-014-9668-6

Sukowati, C.H., Rosso, N., Pascut, D., Anfuso, B., Torre, G., Francalanci, P., Crocè, L.S., and Tiribelli, C. (2012). Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterol., 12.

He, 2019, Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin, Mol. Oncol., 13, 403, 10.1002/1878-0261.12419

Zheng, 2019, CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma, Oncotarget, 10, 7058, 10.18632/oncotarget.27361

Zhao, 2014, Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells, Cell. Signal., 26, 1030, 10.1016/j.cellsig.2014.01.026

Fondevila, 2018, Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors, Exp. Mol. Med., 50, 1

Méndez-Blanco, C., Fondevila, F., Fernández-Palanca, P., García-Palomo, A., van Pelt, J., Verslype, C., González-Gallego, J., and Mauriz, J.L. (2019). Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. Cancers (Basel), 11.

Xu, 2014, Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma, J. Cancer Res. Clin. Oncol., 140, 1507, 10.1007/s00432-014-1713-4

Liu, 2015, Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma, Oncol. Lett., 10, 778, 10.3892/ol.2015.3315

Duran, 2017, Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer, Clin. Cancer Res., 23, 536, 10.1158/1078-0432.CCR-16-0725

Comerford, 2002, Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene, Cancer Res., 62, 3387

Zhu, 2005, Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells, J. Exp. Clin. Cancer Res., 24, 565

Wang, 2017, BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats, Sci. Rep., 7, 9350, 10.1038/s41598-017-09503-8

Zhu, 2017, Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma, Hepatoma Res., 3, 129, 10.20517/2394-5079.2017.14

Piret, 2005, Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis, J. Biol. Chem., 280, 9336, 10.1074/jbc.M411858200

Mendoza, 2011, The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation, Trends Biochem. Sci., 36, 320, 10.1016/j.tibs.2011.03.006

Nymark Aasen, S., Parajuli, H., Hoang, T., Feng, Z., Stokke, K., Wang, J., Roy, K., Bjerkvig, R., Knappskog, S., and Thorsen, F. (2019). Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. Int. J. Mol. Sci., 20.

Pitts, T.M., Newton, T.P., Bradshaw-Pierce, E.L., Addison, R., Arcaroli, J.J., Klauck, P.J., Bagby, S.M., Hyatt, S.L., Purkey, A., and Tentler, J.J. (2014). Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PLoS ONE, 9.

Gedaly, 2010, PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways, Anticancer Res., 30, 4951

Ramanathan, 2014, A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer, JCO, 32, 2588, 10.1200/jco.2014.32.15_suppl.2588

Kordes, 2013, A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer, Investig. New Drugs, 31, 85, 10.1007/s10637-012-9802-1

Heist, 2013, Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial, JCO, 31, 2530, 10.1200/jco.2013.31.15_suppl.2530

Tolcher, 2015, Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma, Cancer Chemother. Pharmacol., 75, 183, 10.1007/s00280-014-2615-5

Bedard, 2015, A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors, Clin. Cancer Res., 21, 730, 10.1158/1078-0432.CCR-14-1814

Zhang, 2018, Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma, Oncol. Lett., 15, 9377

Ye, 2019, The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma, Cell Death Discov., 5, 86, 10.1038/s41420-019-0165-7

Li, 2019, BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway, Am. J. Transl. Res., 11, 5573

Gedaly, 2012, The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment, Anticancer Res., 32, 2531

Kim, 2019, Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma, Cancer Chemother. Pharmacol., 84, 809, 10.1007/s00280-019-03918-y

Newell, 2009, Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo, J. Hepatol., 51, 725, 10.1016/j.jhep.2009.03.028

Papa, 2019, The ERK and JNK pathways in the regulation of metabolic reprogramming, Oncogene, 38, 2223, 10.1038/s41388-018-0582-8

Ye, 2017, Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer, J. Cancer, 8, 3774, 10.7150/jca.21035

Zhang, 2019, Targeting the ROS/PI3K/AKT/HIF-1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2-Deoxy-d-glucose, J. Cell. Mol. Med., 23, 3711, 10.1111/jcmm.14276

Luo, X.-M., Xu, B., Zhou, M.-L., Bao, Y.-Y., Zhou, S.-H., Fan, J., and Lu, Z.-J. (2015). Co-Inhibition of GLUT-1 Expression and the PI3K/Akt Signaling Pathway to Enhance the Radiosensitivity of Laryngeal Carcinoma Xenografts In Vivo. PLoS ONE, 10.

Wang, 2019, The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells, Onco Targets Ther., 12, 5359, 10.2147/OTT.S212465

Tomizawa, 2017, 2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells, Oncol. Lett., 13, 800, 10.3892/ol.2016.5510

Duval, A.P., Troquier, L., de Souza Silva, O., Demartines, N., and Dormond, O. (2019). Diclofenac Potentiates Sorafenib-Based Treatments of Hepatocellular Carcinoma by Enhancing Oxidative Stress. Cancers (Basel), 11.

Mishra, 2018, Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach, FEBS J., 285, 3977, 10.1111/febs.14641

Tanaka, 2012, Iron facilitator LS081 reduces hypoxia-inducible factor-1α protein and functions as anticancer agent in hepatocellular carcinoma, Cancer Sci., 103, 767, 10.1111/j.1349-7006.2011.02192.x

(2020, May 13). Cancer Government—NCI Drug Dictionary—Evofosfamide, Available online: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/evofosfamide.

Borad, 2016, P-100Phase IB study of sorafenib + evofosfamide in patients (pts) with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC): NCCTG N1153 (Alliance), Ann. Oncol., 27, ii29, 10.1093/annonc/mdw199.95

Llovet, 2008, Sorafenib in Advanced Hepatocellular Carcinoma, N. Engl. J. Med., 359, 378, 10.1056/NEJMoa0708857

Sangro, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2

Bruix, 2017, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 389, 56, 10.1016/S0140-6736(16)32453-9

Deeks, 2019, Cabozantinib: A Review in Advanced Hepatocellular Carcinoma, Target. Oncol., 14, 107, 10.1007/s11523-019-00622-y

Meyer, 2018, Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma, N. Engl. J. Med., 379, 54, 10.1056/NEJMoa1717002

Kudo, 2018, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial, Lancet, 391, 1163, 10.1016/S0140-6736(18)30207-1

Zhu, 2019, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 20, 282, 10.1016/S1470-2045(18)30937-9

Zhu, 2018, Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial, Lancet Oncol., 19, 940, 10.1016/S1470-2045(18)30351-6

(2020, May 06). Fda Government—Approved Drugs—FDA Grants Accelerated Approval to Pembrolizumab for Hepatocellular Carcinoma, Available online: https://www.fda.gov/drugs/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma.

Mossenta, M., Busato, D., Baboci, L., Di Cintio, F., Toffoli, G., and Dal Bo, M. (2019). New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma. Cancers (Basel), 11.

Assaraf, 2019, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist. Updates, 46, 100645, 10.1016/j.drup.2019.100645

Gacche, 2018, Redundant angiogenic signaling and tumor drug resistance, Drug Resist. Updates, 36, 47, 10.1016/j.drup.2018.01.002

Kopecka, 2020, Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets, Drug Resist. Updates, 49, 100670, 10.1016/j.drup.2019.100670

Marin, J.J.G., Herraez, E., Lozano, E., Macias, R.I.R., and Briz, O. (2019). Models for Understanding Resistance to Chemotherapy in Liver Cancer. Cancers (Basel), 11.

Taylor, 2015, Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach, Drug Resist. Updates, 23, 69, 10.1016/j.drup.2015.08.004

Wijdeven, 2016, Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics, Drug Resist. Updates, 28, 65, 10.1016/j.drup.2016.07.001

Zhang, J., Song, Q., Wu, M., and Zheng, W. (2020). The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular Carcinoma. Curr. Med. Chem.

Zhitomirsky, 2016, Lysosomes as mediators of drug resistance in cancer, Drug Resist. Updates, 24, 23, 10.1016/j.drup.2015.11.004

Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Altman, 2016, From Krebs to clinic: Glutamine metabolism to cancer therapy, Nat. Rev. Cancer, 16, 619, 10.1038/nrc.2016.71

Boulay, 2017, Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling, Trends Cell Biol., 27, 738, 10.1016/j.tcb.2017.06.002

Suemura, S., Kodama, T., Myojin, Y., Yamada, R., Shigekawa, M., Hikita, H., Sakamori, R., Tatsumi, T., and Takehara, T. (2019). CRISPR Loss-of-Function Screen Identifies the Hippo Signaling Pathway as the Mediator of Regorafenib Efficacy in Hepatocellular Carcinoma. Cancers (Basel), 11.

Goetzman, 2018, The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues, Front. Endocrinol. (Lausanne), 9, 129, 10.3389/fendo.2018.00129

Anderson, 2018, The emerging role and targetability of the TCA cycle in cancer metabolism, Protein Cell, 9, 216, 10.1007/s13238-017-0451-1

Finn, 2020, Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma, N. Engl. J. Med., 382, 1894, 10.1056/NEJMoa1915745

Leone, 2018, Targeting adenosine for cancer immunotherapy, J. Immunother. Cancer, 6, 57, 10.1186/s40425-018-0360-8

De la Cruz-López, K.G., Castro-Muñoz, L.J., Reyes-Hernández, D.O., García-Carrancá, A., and Manzo-Merino, J. (2019). Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches. Front. Oncol., 9.